Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.

Women under 55 with hair loss (AGA) may have a higher risk of heart disease (CAD).

Women with PCOS have higher xanthine oxidase activity linked to inflammation and heart disease risks.

Chemotherapy caused a woman's permanent hair loss and early menopause.

AR gene not major factor in female hair loss; different from male hair loss.

Polycystic ovary syndrome is a common hormonal disorder in women, linked to increased risk of metabolic and heart diseases, and needs more research for better understanding and treatment.

FPHL affects hair density and diameter, causing visible hair loss in older women.

High androgen levels in young women with PCOS are linked to higher blood pressure.

A mother's iron levels early in pregnancy can influence the DNA makeup of her child, potentially affecting the child's health.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.

Early diagnosis and treatment of PCOS in young people is important to prevent long-term health problems.

Hair transplants are highly satisfactory for treating female-pattern hair loss.

Aging-related hormone changes affect voice quality, especially during puberty, menstruation, pregnancy, and menopause.

Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.

Overweight women with PCOS are more likely to have excess male hormones.

A young woman had a rare tumor causing high male hormone levels and symptoms like excessive hair and acne. After removing the tumor, her hormone levels returned to normal. Early diagnosis is important.

Intralesional corticosteroids and 5-alpha-reductase inhibitors are the best treatments for frontal fibrosing alopecia.

Obesity leads to physical, metabolic, reproductive issues, higher healthcare costs, and mental health problems.

Spinach-derived thylakoid supplements plus a low-calorie diet helped obese women with polycystic ovary syndrome lose weight and improve their metabolism.

AMH levels in adolescents with PCOS are not affected by their weight.

Hormone therapy in transgender individuals can increase acne and affect hair growth and loss.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

Different treatments for PCOS focus on the specific symptoms, with weight loss and lifestyle changes being important.

DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.

Women with severe types of PCOS are more likely to have metabolic syndrome, and belly fat is a key predictor of this risk.

Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.

The paper suggests that France's suspension of Diane-35 was hasty and could cause treatment issues and unintended pregnancies, recommending a re-evaluation and better patient information.

Longer GGN repeats in the androgen receptor gene are linked to polycystic ovary syndrome.

The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.

Testosterone implants in women require pharmacological dosing to be effective and are generally safe and well-tolerated.